Following a joint meeting of the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development underscores its position that ACTOS (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.
Actively screening people aged 65 or over in the community improves the detection of atrial fibrillation (irregular heart rhythm), a major risk factor for stroke, finds a study published online today.
GlaxoSmithKline (LSE & NYSE: GSK) and POZEN Inc. (NASDAQ: POZN) announced that the U.S. Food and Drug Administration (FDA) has issued a second approvable letter for Trexima? (sumatriptan/naproxen sodium).
Multidetector computed tomography angiography is highly accurate in depicting intracranial aneurysms, according to a study published in the August issue of Radiology. In addition, MDCT angiography can be used to quickly determine the possibility of using minimally invasive treatment rather than open surgery.
People with dieting blues should try swapping white corn tortillas for blue. A recent study suggests that the coloured flatbreads are healthier, especially for diabetics and dieters, Sara Jensen reports in Chemistry & Industry, the magazine of the SCI.
A pair of large-scale genetic studies supported by the National Institutes of Health has revealed two genes that influence the risk of getting multiple sclerosis (MS) ? data sought since the discovery of the only other known MS susceptibility gene decades ago.
Twenty-one years after they first described a fatal genetic disorder in Missouri and Arkansas families, scientists at Washington University School of Medicine in St. Louis have linked the condition to mutations in a gene known as TREX1.
This is an analysis of existing data that has been previously published (online in Diabetes Care, 29 May 2007) and provides no new information on the risk of heart failure associated with the thiazolinediones (TZD) class.
The U.S. Food and Drug Administration announced that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet specific guidelines.
Health Canada is advising consumers not to use Liviro3, a natural health product marketed for sexual enhancement, due to concerns about possible side-effects. The product is not authorized for sale in Canada and has not been found in the Canadian marketplace, but is for sale on the Internet, and may have been brought into the country by travellers.